HeartSciences Announces Major Milestone with the Issuance of CPT® Codes by the American Medical Association for ECG AI Analysis of Cardiac Dysfunction
19 oct. 2022 09h15 HE
|
Heart Test Laboratories, Inc.
SOUTHLAKE, Texas, Oct. 19, 2022 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), a medical technology company focused...
HeartSciences Granted U.S Patent for ECG Assessment of Heart Diastolic Function Using Artificial Intelligence
20 sept. 2022 08h30 HE
|
Heart Test Laboratories, Inc.
Southlake, Texas, Sept. 20, 2022 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), a medical technology company focused...
HeartSciences Provides Business Update and Reports First Quarter Fiscal 2023 Financial Results
13 sept. 2022 08h00 HE
|
Heart Test Laboratories, Inc.
Nearing Completion of Patient Recruitment in FDA Pivotal Clinical Validation Study of MyoVista® Remains on Track for MyoVista® FDA De Novo Resubmission in Current Fiscal Year Southlake, Texas,...
HeartSciences to Participate and Showcase the MyoVista at the Inauguration Ceremony of the Center for Innovation at Rutgers Robert Wood Johnson University Hospital
12 sept. 2022 08h30 HE
|
Heart Test Laboratories, Inc.
Southlake, Texas, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc d.b.a HeartSciences (NASDAQ: HSCS), a medical technology company focused on applying innovative AI-based technology...
HeartSciences to Present at the H.C. Wainwright 24th Annual Global Investment Conference
08 sept. 2022 08h30 HE
|
Heart Test Laboratories, Inc.
Southlake, Texas, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), a medical technology company focused...
HeartSciences Provides Corporate Update and Reports Fiscal 2022 Financial Results
01 août 2022 08h30 HE
|
Heart Test Laboratories, Inc.
MyoVista FDA De Novo Resubmission Expected in Current Fiscal Year Completed IPO in June 2022 with Approximately $6.375M of Gross Proceeds Listed on NASDAQ Capital Market under Ticker HSCS ...
HeartSciences CEO to Participate in the Benzinga All Access Event on July 15th
13 juil. 2022 14h03 HE
|
Heart Test Laboratories, Inc.
Southlake, Texas, July 13, 2022 (GLOBE NEWSWIRE) -- HeartSciences (NASDAQ: HSCS; HSCSW) (“Company”), a medical technology company focused on applying innovative AI-based technology to an ECG (also...
Heart Test Laboratories, Inc. Announces Pricing of $6.375 Million Initial Public Offering and Nasdaq Listing
15 juin 2022 09h50 HE
|
Heart Test Laboratories, Inc.
SOUTHLAKE, Texas, June 15, 2022 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), a medical technology company focused on applying...